摘要
Source: Giolito A, Levy C, Varon E, et al. Adjunctive dexamethasone and 30- day all-cause death after hospital admission in paediatric pneumococcal meningitis: a propensity score analysis. Lancet Child Adolesc Health. 2025;9(4):255-261; doi: 10.1016/S2352-4642(25)00029-X.Investigators from multiple institutions in France conducted a retrospective study to assess the effect of dexamethasone in reducing 30-day, all-cause mortality in children with pneumococcal meningitis. For the study, they abstracted data from a French national surveillance system that includes data on patients with confirmed bacterial meningitis who received care at 1 of 238 sites in France. Demographic, clinical, and outcome data are included in the database. Study participants were children <18 years old with pneumococcal meningitis between 2005 and 2022. The diagnosis was confirmed by a positive cerebrospinal fluid (CSF) culture, antigen test, PCR, or a positive blood culture associated with CSF pleocytosis. Patients who did not receive a third-generation cephalosporin were excluded. Study participants were classified by whether they received dexamethasone 0.15 mg/kg every 6 hours for 4 days (per national guidelines) or no dexamethasone (control group). The primary outcome was all-cause, 30-day mortality. Secondary outcomes included hearing loss and neurologic complications (eg, seizures). Infection complications, such as intracerebral empyema, recurrent meningitis, and septic thrombosis were included as a safety outcome. Outcomes were compared between those in the dexamethasone and control groups using logistic regression. A propensity score-based analysis was used to account for multiple clinical and demographic characteristics.Data were analyzed on 1,231 study participants, including 581 who received dexamethasone and 650 controls. The median age of study participants was 1.1 years. There was a change in pneumococcal serotype associated with meningitis after the PCV13 vaccine was implemented in France in 2010. Prior to 2010, 60% of patients had PCV13 serotypes, and after that, 86% had non-PCV13 serotypes. Among the group of study children who received dexamethasone as an adjunct treatment, 36 (6%) died within 30 days; 69 (12%) of those in the control group died (adjusted odds ratio [aOR], 0.39; 95% confidence interval [CI], 0.23, 0.65). The use of dexamethasone was associated with a decreased risk of death among patients 1–5 years old (aOR, 0.30; 95% CI, 0.10, 0.88) and those >5 years of age (aOR, 0.14; 95% CI, 0.03, 0.64). The association was attenuated in infants <1 year old (aOR, 0.53; 95% CI, 0.28, 1.01). There were no significant differences between patients in the dexamethasone and control groups in rate of hearing loss (aOR, 1.08; 95% CI, 0.43, 2.73), neurologic complications (aOR, 1.13; 95% CI, 0.83, 1.53), or infectious complications (aOR, 0.79; 95% CI, 0.41, 1.53).The authors conclude that use of dexamethasone was associated with a decreased risk of death in children with pneumococcal meningitis.Dr Loyal has disclosed no financial relationship relevant to this commentary. This commentary does not contain a discussion of an unapproved/investigative use of a commercial product/device.S. pneumoniae strains not covered by vaccination remain a formidable threat to children.1 In the current study, French investigators demonstrate that dexamethasone administered to children with pneumococcal meningitis within 12 hours of initiation of antimicrobials lowered the risk of mortality. Strengths of the study include multiple sites participating in a national surveillance system, confirmed pneumococcal meningitis, and data spanning almost 18 years. In the absence of randomized controlled studies (RCTs), the investigators chose to perform a propensity score analysis, which allows for mitigating bias and mimicking an RCT using retrospective observational data.A propensity score acts as a surrogate for all the covariates used to estimate the probability of 1 study participant being assigned to the treatment group or control group based on the participant’s characteristics or pre-treatment conditions.2 In this study, the investigators created propensity scores by estimating the probability of receiving dexamethasone for each patient using baseline covariates (eg, demographics, clinical condition, laboratory results, disease management) and logistic regression. To balance the groups more fairly, each patient was given a 'stabilized weight,' which was based on the inverse of their probability of receiving dexamethasone. This created a 'pseudo-randomized' group for comparison and smooths out extreme values. The limitation with this type of analysis is the inability to control for unmeasured confounders.The investigators reference 2 studies in which the effectiveness of vancomycin was lowered in the presence of dexamethasone.3,4 In 1 study in rabbits with pneumococcal infection, levels of vancomycin in the CSF were lower in the group treated with dexamethasone.3 The second study was a case report of 2 patients with pneumococcal meningitis whose CSF still contained S. pneumoniae on days 6 and 10 of illness despite antimicrobial treatment.4 The authors surmised that dexamethasone administration may have affected penetration of antibiotics into the CSF.4 The lack of more robust data to elucidate the effects of dexamethasone on antimicrobial penetration in the CSF is problematic, especially in the context of the current study showing reduced mortality.The concomitant use of dexamethasone with antimicrobial therapy in children with pneumococcal meningitis appears to lower mortality.Despite the absence of long-term follow-up to assess hearing and neurologic sequelae, the results of the current study can inform future guidelines on the use of dexamethasone in the treatment of the leading cause of bacterial meningitis worldwide, S. pneumoniae.